These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

413 related articles for article (PubMed ID: 22522582)

  • 21. US Food and Drug Administration approval of drugs for the treatment of prostate cancer: a new era has begun.
    D'Amico AV
    J Clin Oncol; 2014 Feb; 32(4):362-4. PubMed ID: 24344221
    [No Abstract]   [Full Text] [Related]  

  • 22. [Management of metastatic castration-resistant prostate cancer following docetaxel].
    Beuzeboc P; Ropert S; Goldwasser F; Zerbib M
    Bull Cancer; 2012 Jul; 99 Suppl 1():S66-72. PubMed ID: 22516457
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinical implications for a treatment algorithm and differential indication to hormone therapy and chemotherapy options in metastatic castrate-resistant prostate cancer: a personal view.
    Bracarda S; Sisani M; Marrocolo F; Hamzaj A; Del Buono S; Altavilla A
    Expert Rev Anticancer Ther; 2014 Nov; 14(11):1283-94. PubMed ID: 25353258
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Novel therapeutic strategies for metastatic prostate cancer in the post-docetaxel setting.
    Sartor O; Michels RM; Massard C; de Bono JS
    Oncologist; 2011; 16(11):1487-97. PubMed ID: 22048000
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Bone targeted therapies for the prevention of skeletal morbidity in men with prostate cancer.
    Saylor PJ
    Asian J Androl; 2014; 16(3):341-7. PubMed ID: 24435057
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Abiraterone acetate in castration-resistant prostate cancer.
    Iacovelli R; Palazzo A; Procopio G; Gazzaniga P; Cortesi E
    Anticancer Drugs; 2012 Mar; 23(3):247-54. PubMed ID: 22123334
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efficacy, patient-reported outcomes (PROs), and tolerability of the changing therapeutic landscape in patients with metastatic prostate cancer (MPC): a systematic literature review.
    Seal BS; Asche CV; Puto K; Allen PD
    Value Health; 2013; 16(5):872-90. PubMed ID: 23947983
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Management of androgen-independent prostate cancer.
    Diaz M; Patterson SG
    Cancer Control; 2004; 11(6):364-73. PubMed ID: 15625524
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Advances in prevention and treatment of bone metastases in prostate cancer. Role of RANK/RANKL inhibition.
    Gomez-Veiga F; Ponce-Reixa J; Martinez-Breijo S; Planas J; Morote J
    Actas Urol Esp; 2013 May; 37(5):292-304. PubMed ID: 23246105
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparison of abiraterone acetate versus ketoconazole in patients with metastatic castration resistant prostate cancer refractory to docetaxel.
    Peer A; Gottfried M; Sinibaldi V; Carducci MA; Eisenberger MA; Sella A; Leibowitz-Amit R; Berger R; Keizman D
    Prostate; 2014 Apr; 74(4):433-40. PubMed ID: 24338986
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prostate-specific antigen response to deferred combined androgen blockade therapy using bicalutamide predicts survival after subsequent oestrogen and docetaxel therapies in patients with castration-resistant prostate cancer.
    Kijima T; Fujii Y; Yokoyama M; Ishioka J; Matsuoka Y; Numao N; Saito K; Koga F; Masuda H; Kawakami S; Kihara K
    BJU Int; 2012 Oct; 110(8):1149-55. PubMed ID: 22369348
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Commentary on "Comparison of abiraterone acetate versus ketoconazole in patients with metastatic castration resistant prostate cancer refractory to docetaxel." Peer A, Gottfried M, Sinibaldi V, Carducci MA, Eisenberger MA, Sella A, Leibowitz-Amit R, Berger R, Keizman D, Department of Oncology, Rambam Medical Center, Haifa, Israel.: Prostate 2014 Apr;74(4):433-40; doi:10.1002/pros.22765. [Epub 2013 Dec 11].
    Trump D
    Urol Oncol; 2016 May; 34(5):247. PubMed ID: 25907623
    [TBL] [Abstract][Full Text] [Related]  

  • 33. New perspectives in the therapy of castration resistant prostate cancer.
    Rescigno P; Buonerba C; Bellmunt J; Sonpavde G; De Placido S; Di Lorenzo G
    Curr Drug Targets; 2012 Dec; 13(13):1676-86. PubMed ID: 23043326
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Combination of docetaxel, estramustine phosphate, and zoledronic acid in androgen-independent metastatic prostate cancer: efficacy, safety, and clinical benefit assessment.
    Efstathiou E; Bozas G; Kostakopoulos A; Kastritis E; Deliveliotis C; Antoniou N; Skarlos D; Papadimitriou C; Dimopoulos MA; Bamias A
    Urology; 2005 Jan; 65(1):126-30. PubMed ID: 15667877
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Novel agents for the therapy of castration-resistant prostate cancer: overview of pivotal studies and new strategies to come].
    Ouzaid I; Ravery V; Pouessel D; Culine S
    Prog Urol; 2013 Jan; 23(1):1-7. PubMed ID: 23287477
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Metastatic hormone-sensitive prostate cancer].
    Gravis G; Salem N; Walz J
    Bull Cancer; 2015 Jan; 102(1):57-64. PubMed ID: 25609491
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Preventing bone complications in prostate cancer.
    Bishr M; Saad F
    Curr Opin Support Palliat Care; 2012 Sep; 6(3):299-303. PubMed ID: 22871982
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Additive effect of zoledronic acid on serum prostate-specific antigen changes for hormone-sensitive prostate cancer patients with bone metastasis treated by combined androgen blockade.
    Kamiya N; Suzuki H; Endo T; Takano M; Yano M; Naoi M; Nishimi D; Kawamura K; Imamoto T; Ichikawa T
    Int J Urol; 2012 Feb; 19(2):169-73. PubMed ID: 22126137
    [TBL] [Abstract][Full Text] [Related]  

  • 39. New treatment options for castrate-resistant prostate cancer: a urology perspective.
    Gomella LG; Gelpi F; Kelly WK
    Can J Urol; 2011 Aug; 18(4):5767-77. PubMed ID: 21854708
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cost-effectiveness of denosumab vs zoledronic acid for prevention of skeletal-related events in patients with solid tumors and bone metastases in the United States.
    Stopeck A; Rader M; Henry D; Danese M; Halperin M; Cong Z; Qian Y; Dansey R; Chung K
    J Med Econ; 2012; 15(4):712-23. PubMed ID: 22409231
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.